Transarterial chemoembolization for hepatocellular carcinoma: 2023 Expert consensus-based practical recommendations of the Korean Liver Cancer Association
- Author:
Yuri CHO
1
;
Jin Woo CHOI
;
Hoon KWON
;
Kun Yung KIM
;
Byung Chan LEE
;
Hee Ho CHU
;
Dong Hyeon LEE
;
Han Ah LEE
;
Gyoung Min KIM
;
Jung Suk OH
;
Dongho HYUN
;
In Joon LEE
;
Hyunchul RHIM
;
Author Information
- Publication Type:Guideline
- From:Clinical and Molecular Hepatology 2023;29(3):521-541
- CountryRepublic of Korea
- Language:English
- Abstract: Transarterial chemoembolization (TACE) was introduced in 1977 with the administration of chemotherapeutic agent to gelatin sponge particles through the hepatic artery in patients with hepatocellular carcinoma (HCC) and was established as conventional TACE using Lipiodol in the 1980s. In the 2000s, drug-eluting beads were developed and applied clinically. Currently, TACE is a commonly used non-surgical treatment modality for patients with HCC who are unsuitable for curative treatment. Considering the vital role of TACE in the management of HCC, it is crucial to organize current knowledge and expert opinions regarding patient preparation, procedural techniques, and post-treatment care in TACE, which can enhance therapeutic efficacy and safety. A group of 12 experts in the fields of interventional radiology and hepatology, convened by the Research Committee of the Korean Liver Cancer Association (KLCA), has developed expert consensus-based practical recommendations in TACE. These recommendations have been endorsed by the Korean Society of Interventional Radiology and provide useful information and direction in performing TACE procedure as well as pre- and post- procedural patient care.
